Literature DB >> 16722152

[Effect of administration of Escherichia coli Nissle (Mutaflor) on intestinal colonisation, endo-toxemia, liver function and minimal hepatic encephalopathy in patients with liver cirrhosis].

J Lata1, J Juránková, V Príbramská, P Fric, M Senkyrík, P Díte, R Kroupa.   

Abstract

The purpose of the study was to verify effects of Escherichia coli Nissle (Mutaflor) on intestinal colonisation, endotoxin levels, hepatic encephalopathy and liver function in patients with liver cirrhosis. The study involved 39 patients (22 taking Mutaflor and 17 taking placebo). Even though the number combination test showed extended reaction time in patients with described minimal hepatic encephalopathy the drop was not significant in the trend evaluation. However, the treated group displayed significant improvement of intestinal colonisation (p < 0.001) and a trend towards significant reduction of endotoxin levels on day 42 (p = 0.07) and improvement of liver function assessed with the Child-Pugh classification on days 42 and 84 (p = 0.06). Probiotic preparations can therefore represent a significant contribution to this group therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16722152

Source DB:  PubMed          Journal:  Vnitr Lek        ISSN: 0042-773X


  9 in total

Review 1.  Gut microbiota and hepatic encephalopathy.

Authors:  Radha K Dhiman
Journal:  Metab Brain Dis       Date:  2013-03-06       Impact factor: 3.584

Review 2.  Probiotics for people with hepatic encephalopathy.

Authors:  Rohan Dalal; Richard G McGee; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

Review 3.  Clinical and pathophysiological consequences of alterations in the microbiome in cirrhosis.

Authors:  Jane Macnaughtan; Rajiv Jalan
Journal:  Am J Gastroenterol       Date:  2015-09-29       Impact factor: 10.864

Review 4.  The Current Hepatic Encephalopathy Pipeline.

Authors:  Alexander J Ryu; Robert S Rahimi; Michael D Leise
Journal:  J Clin Exp Hepatol       Date:  2020-01-14

Review 5.  The overarching influence of the gut microbiome on end-organ function: the role of live probiotic cultures.

Authors:  Luis Vitetta; Rachel Manuel; Joyce Yusi Zhou; Anthony W Linnane; Sean Hall; Samantha Coulson
Journal:  Pharmaceuticals (Basel)       Date:  2014-09-19

Review 6.  Insights from 100 Years of Research with Probiotic E. Coli.

Authors:  Trudy M Wassenaar
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2016-09-29

7.  Prevention and treatment of urinary tract infection with probiotics: Review and research perspective.

Authors:  D Borchert; L Sheridan; A Papatsoris; Z Faruquz; J M Barua; I Junaid; Y Pati; F Chinegwundoh; N Buchholz
Journal:  Indian J Urol       Date:  2008-04

8.  Probiotic as a novel treatment strategy against liver disease.

Authors:  Abbas Ali Imani Fooladi; Hamideh Mahmoodzadeh Hosseini; Mohammad Reza Nourani; Soghra Khani; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2013-02-25       Impact factor: 0.660

9.  Translational Development of Microbiome-Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates.

Authors:  Caroline Kurtz; William S Denney; Larry Blankstein; Sarah E Guilmain; Suman Machinani; Jonathan Kotula; Saurabh Saha; Paul Miller; Aoife M Brennan
Journal:  Clin Transl Sci       Date:  2017-12-01       Impact factor: 4.689

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.